Analysis of related influencing factors of active tuberculosis complicated with acute pulmonary thromboembolism

doi:10.11958/20241508

Abstract

Abstract:

Objective To analyze the factors affecting patients with active tuberculosis (ATB) combined with acute pulmonary thromboembolism (APTE), in order to intervene the progression of the patients' disease early and improve the prognosis. Methods A total of 121 patients with ATB were studied. Forty-one cases with APTE diagnosed by CT pulmonary arteriography (CTPA) were in the ATB+APTE group, and 80 patients with ATB were in the ATB group. The general data of the two groups were collected and analyzed, including the differences in TB lesion sites and drug resistance, clinical manifestations and first laboratory indexes after admission. The influencing factors of ATB patients with concurrent APTE were analyzed by multifactorial Logistic regression, and continuous indexes with significant differences were selected, and the subjects' work characteristics (ROC) curves were plotted to assess the predictive value. Results Compared with the ATB group, patients in the ATB+APTE group were older, and Padua scores were higher, red blood cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), D-dimer were higher, the proportion of cough and expectoration increased and levels of partial pressure of carbon dioxide, hemoglobin (Hb), and albumin were lower (P<0.05). Multifactorial Logistic regression analysis showed that higher Padua score, RDW and D-dimer were risk factors for patients with ATB combined with APTE, and the predicted area under the curve (AUC) for ATB combined with APTE were 0.657 (95%CI: 0.549-0.764) and 0.889 (95%CI: 0.827-0.951) for RDW and D-dimer, respectively. Conclusion In patients with ATB, the risk of combined APTE is increased with increased frequency of sputum and elevated Padua score, RDW and D-dimer, alerting to the development of APTE events.

Key words: tuberculosis, pulmonary, pulmonary embolism, root cause analysis

CLC Number:

R521.9

Figures/Tables 7

References 20

[1]	WHO. WHO Global tuberculosis report 2024[EB/OL]. (2024-10-29)[2024-11-15]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024.
[2]	KAHN S R, DE WIT K. Pulmonary embolism[J]. N Engl J Med, 2022, 387(1):45-57. doi:10.1056/NEJMcp2116489.
[3]	HUANG L, YIN C, GU X, et al. Severe pulmonary tuberculosis complicated with insidious pulmonary thromboembolism:a case report and literature review[J]. J Thromb Thrombolysis, 2020, 49(4):644-650. doi:10.1007/s11239-019-01967-x.
[4]	KERAMIDAS G, GOURGOULIANIS K I, KOTSIOU O S. Venous thromboembolic disease in chronic inflammatory lung diseases:knowns and unknowns[J]. J Clin Med, 2021, 10(10):2061. doi:10.3390/jcm10102061.
[5]	DANWANG C, BIGNA J J, AWANA A P, et al. Global epidemiology of venous thromboembolism in people with active tuberculosis:a systematic review and meta-analysis[J]. J Thromb Thrombolysis, 2021, 51(2):502-512. doi:10.1007/s11239-020-02211-7.
[6]	ALAWAD M J, ALBUNI M K, SUBAHI E A, et al. Rifampicin-induced pulmonry embolism:a rare side effect[J]. Cureus, 2021, 13(10):e18904. doi:10.7759/cureus.18904.
[7]	ZHOU X, YANG Y, ZHAI Z, et al. Clinical characteristics and mortality predictors among very old patients with pulmonary thromboembolism:a multicenter study report[J]. BMC Pulm Med, 2024, 24(1):26. doi:10.1186/s12890-023-02824-7.
[8]	DI BARI V, GUALANO G, MUSSO M, et al. Increased association of pulmonary thromboembolism and tuberculosis during COVID-19 pandemic:data from an Italian infectious disease referral hospital[J]. Antibiotics (Basel), 2022, 11(3):398. doi:10.3390/antibiotics11030398.
[9]	CHEDID C, KOKHREIDZE E, TUKVADZE N, et al. Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study[J]. Int J Infect Dis, 2020, 100:199-206. doi:10.1016/j.ijid.2020.09.017.
[10]	GU Z, LIU B, YU X, et al. Association of blood neutrophil-lymphocyte ratio with short-term prognosis and severity of tuberculosis meningitis patients without HIV infection[J]. BMC Infect Dis, 2023, 23(1):449. doi:10.1186/s12879-023-08438-y.
[11]	SHARIF-KASHANI B, AZIMI M, TABARSI P, et al. Investigation of two general venous thromboembolism risk-stratification models in predicting venous thromboembolic events in TB patients[J]. Int J Mycobacteriol, 2022, 11(1):83-87. doi:10.4103/ijmy.ijmy_252_21.
[12]	FELKER G M, ALLEN L A, POCOCK S J, et al. Red cell distribution width as a novel prognostic marker in heart failure:data from the CHARM Program and the Duke Databank[J]. J Am Coll Cardiol, 2007, 50(1):40-47. doi:10.1016/j.jacc.2007.02.067.
[13]	TONELLI M, SACKS F, ARNOLD M, et al. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease[J]. Circulation, 2008, 117(2):163-168. doi:10.1161/CIRCULATIONAHA.107.727545.
[14]	FEBRA C, SPINU V, FERREIRA F, et al. Predictive value for increased red blood cell distribution width in unprovoked acute venous thromboembolism at the emergency department[J]. Clin Appl Thromb Hemost, 2023, 29:10760296231193397. doi:10.1177/10760296231193397.
[15]	MELEKOĞLU A, ÖZKAN S, ÖZTÜRK D. Relationship between hematological parameters and mortality in patients with acute PTE[J]. Global Emergency and Critical Care (Online), 2023, 2(1). doi:10.4274/globecc.galenos.2023.00719.
[16]	JOOSSE H J, VAN OIRSCHOT B A, KOOIJMANS S A A, et al. In-vitro and in-silico evidence for oxidative stress as drivers for RDW[J]. Sci Rep, 2023, 13(1):9223. doi: 10.1038/s41598-023-36514-5.
[17]	YU F T, ARMSTRONG J K, TRIPETTE J, et al. A local increase in red blood cell aggregation can trigger deep vein thrombosis:evidence based on quantitative cellular ultrasound imaging[J]. J Thromb Haemost, 2011, 9(3):481-488. doi:10.1111/j.1538-7836.2010.04164.x.
[18]	GERSH K C, NAGASWAMI C, WEISEL J W. Fibrin network structure and clot mechanical properties are altered by incorporation of erythrocytes[J]. Thromb Haemost, 2009, 102(6):1169-1175. doi:10.1160/TH09-03-0199.
[19]	ESMON C T, XU J, LUPU F. Innate immunity and coagulation[J]. J Thromb Haemost, 2011, 9(Suppl 1):182-188. doi:10.1111/j.1538-7836.2011.04323.x.
[20]	KAGER L M, BLOK D C, LEDE I O, et al. Pulmonary tuberculosis induces a systemic hypercoagulable state[J]. J Infect, 2015, 70(4):324-334. doi:10.1016/j.jinf.2014.10.006.

组别	n		男性	年龄/岁		吸烟			饮酒			Padua评分
ATB组	80		53（66.3）	57（42，67）		38（47.5）			20（25.0）			1（0，1）
ATB+APTE组	41		28（68.3）	68（52，74）		18（43.9）			5（12.2）			2（1，5）
χ²或Z			0.051	2.736^＊		0.141			2.711			5.016^＊＊
组别		p（CO₂）/mmHg			高血压			糖尿病			冠心病
ATB组		38.1（35.3，41.2）			13（16.3）			23（28.8）			10（12.5）
ATB+APTE组		34.6（30.3，37.7）			5（12.2）			10（24.4）			10（24.4）
Z或χ²		4.444^＊＊			0.352			0.260			2.778
组别		慢性肺部疾病			癌症		细菌性肺炎			真菌性肺炎
ATB组		7（8.8）			0		54（67.5）			5（6.3）
ATB+APTE组		1（2.4）			1（2.4）		30（73.2）			1（2.4）
χ²		0.876			0.117		0.411			0.222

组别	n		男性	年龄/岁		吸烟			饮酒			Padua评分
ATB组	80		53（66.3）	57（42，67）		38（47.5）			20（25.0）			1（0，1）
ATB+APTE组	41		28（68.3）	68（52，74）		18（43.9）			5（12.2）			2（1，5）
χ²或Z			0.051	2.736^＊		0.141			2.711			5.016^＊＊
组别		p（CO₂）/mmHg			高血压			糖尿病			冠心病
ATB组		38.1（35.3，41.2）			13（16.3）			23（28.8）			10（12.5）
ATB+APTE组		34.6（30.3，37.7）			5（12.2）			10（24.4）			10（24.4）
Z或χ²		4.444^＊＊			0.352			0.260			2.778
组别		慢性肺部疾病			癌症		细菌性肺炎			真菌性肺炎
ATB组		7（8.8）			0		54（67.5）			5（6.3）
ATB+APTE组		1（2.4）			1（2.4）		30（73.2）			1（2.4）
χ²		0.876			0.117		0.411			0.222

组别	n	肺结核	肺结核合并肺外结核	耐药^#
ATB组	80	76（95.0）	4（5.0）	9（14.1）
ATB+APTE组	41	39（95.1）	2（4.9）	5（16.7）
χ²		0.001		0.109

组别	n	肺结核	肺结核合并肺外结核	耐药^#
ATB组	80	76（95.0）	4（5.0）	9（14.1）
ATB+APTE组	41	39（95.1）	2（4.9）	5（16.7）
χ²		0.001		0.109

组别	n	咳嗽	咳痰	胸痛	咯血
ATB组	80	52（65.0）	32（40.0）	12（15.0）	10（12.5）
ATB+APTE组	41	36（87.8）	31（75.6）	7（17.1）	5（12.2）
χ²		7.108^＊＊	13.773^＊＊	0.088	0.002